PMID: 39043357 | doi:10.1016/j.physbeh.2024.114644 Rahman OF et al
This review evaluates the modern and latest research on the application of MB for treating AD
Findings presented at the Clinical Trials on Alzheimers Disease 2025 Congress in San Diego in December 2025 from the EVOKE and EVOKE+ Phase III studies evaluating oral semaglutide in early Alzheimers disease did not meet the main cognitive endpoint despite biomarker signals underscoring the translational gap between metabolic modulation and the complex nature of neurodegenerative processes
White fat stores energy passively
The second thing it tells us is that the statistical models are going to be seriously biased because once you have that many dropouts, and if, especially if theyre disparate between groups, then your estimate of the weight loss difference is going to be biased
doi: 10.1007/s00134-023-07263-w [PubMed] 38170117 Gidal BE, Resnick T, Smith MC, Wheless JW